Supernus and Indivior complete merger
INDV•Supernus completed its merger with Indivior on November 2, 2026, creating a combined CNS biopharmaceutical company operating as Supernus. Former Indivior shareholders own approximately 56.5% of the company, and a one-time $1 billion cash dividend will go to pre-closing Indivior shareholders.
1. Merger completed
The combined company begins trading on the Nasdaq Global Market under ticker SUPN on November 3, 2026. Former Supernus shareholders received 1.5401 common shares for each share held and own approximately 43.5% of the combined company; former Indivior shareholders own approximately 56.5%. The $1 billion special cash dividend for pre-closing Indivior shareholders is funded by a $650 million Citibank term loan facility and existing cash.
